Stocks of most companies present in these deals is soaring
Mumbai, India -- (SBWIRE) -- 09/24/2013 -- With many deals valued at over $8 billion, 2013 is turning out be one of the biggest Pharma Acquisitions Deals Year. Most of these companies’ stocks are soaring since the announcements.
Amgen Inc & Onyx Pharmaceuticals
Amgen, in August, agreed to buy Onyx Pharmaceuticals for about $10.4 billion in cash to gain access to the company’s three anticancer treatments. Amgen’s purchase ranks among the five biggest-ever takeovers of a biotechnology company.
Onyx’s Kyprolis was approved in the United States last July as a last-ditch treatment for multiple myeloma, a bone marrow cancer. The drug recorded sales of $125 million in the first six months of this year.
Onyx has also been developing an oral proteasome inhibitor, a product called Oprozomib and this is a product that is currently in Phase 2 for the treatment of relapse refractory multiple myeloma patients.
Amgen presented at the Bank of America-Merrill Lynch Global Healthcare Conference on 13 September 2013.
Amgen, the world’s largest biotech company, also makes a move in Japan. It recently entered into a long-term collaboration with Astellas Pharma Inc and will form a joint venture with the Japanese drugmaker to provide new medicines in Japan. The alliance will help accelerate development and commercialization of Amgen medicines for patients in Japan.
Transcript of Amgen’s Acquisition Conference Call
Valeant Pharmaceuticals and Bausch & Lomb
Valeant Pharmaceuticals announced in May that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion. This deal will transform Valeant into a leader in eye health.
Bausch + Lomb is the leading global healthcare eye health company with significant presence in all the major segments of eye healthcare including prescription drugs, surgical products and the OTC consumer segment.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Michael Pearson, CEO of Valeant said in the acquisition conference call that “Many of the markets Bausch + Lomb competes in are complementary to Valeant's including Russia, Poland and parts of Southeast Asia. However, through this acquisition we will have critical mass in additional emerging markets such as China, the Middle-East, South Korea and Turkey. We expect these actions to result in at least $800 million of annual run rate cost synergies between these two companies by the end of 2014”
Valeant's Acquisition Conference Call
Actavis Inc. & Warner Chillcott
Generic drugmaker Actavis (ACT) has received shareholder approval for its acquisition of Warner Chilcott (WCRX)
Actavis announced that three large, independent proxy advisory firms have recommended that Activis shareholders vote in favor of the company's agreement to acquire Warner Chilcott (WCRX)
Actavis, in May announced plans to acquire Ireland's Warner Chilcott for $8.5 billion. The deal will bolster Actavis' lineup of women's health and gastroenterology products. Ireland-based Warner Chilcott specializes in drugs in the areas of urology, gastroenterology, dermatology and women's health. The deal is expected to close by the end of the year.
Last October, Watson Pharmaceuticals closed its $5.9 billion acquisition of Swiss partner Actavis. After Watson bought Actavis, it changed its corporate name to Actavis Inc. The acquisition made it the third largest drug maker in the world.
Actavis Inc is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.
Actavis Q2 Earnings Details
Perrigo Company & Elan Corporation
Perrigo announced in July that Perrigo and Elan have entered into a definitive agreement under which Elan will be acquired by a new holding company incorporated in Ireland. The cash and stock transaction is valued at $8.6 billion or $6.7 billion net of cash, which combines two great companies to create a global healthcare company with an industry-leading growth profile and with geographic scale and scope to continue building a truly differentiated business.
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products and active pharmaceutical ingredients (API). The Company is the store brand manufacturer of OTC pharmaceutical products and infant formulas.
Elan Corporation, plc is a biotechnology company focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases.
Joseph C. Papa, CEO of Perrigo, said in the acquisition conference call that “Perrigo received an escalated royalty stream from Tysabri, a rapidly growing, high-margin, blockbuster product with $1.6 billion in revenue. Tysabri is without a doubt one of the most important and efficacious treatment for people suffering from Multiple Sclerosis, a debilitating disease. The transaction will get access to a Phase 2 central nervous system product that's approaching a key milestone.”
He also stated that Perrigo will receive $1.9 billion in cash from the Elan balance sheet. Elan shareholders will receive $6.25 in cash and 0.07636 shares of new Perrigo for each Elan share.
Earnings Impact Launches Ideaz
Ideaz are a collection of articles on currently trending stocks and topics which are making headlines. Certain articles provide you a graphical perspective of reasons behind why a company or its product stays in the news.
Earnings Impact Launches Analyz Thiz
Analyz Thiz helps you understand the correlation between the time when a company’s conference call transcript is available and the effect it has on its stock price at that point in time.
About Editor’s Picks
The latest feature on Earnings Impact is Editor's Picks, where a selection of game-changing transcripts are listed which explain why those companies are in the news.
About Earnings Impact
Earningsimpact.com is the destination for Transcripts of events that could impact stocks and its stakeholders. Transcripts are posted on earningsimpact.com within 2 hours of the live event. Active investors and traders will get access to this vital information much before the market reacts.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)